Misplaced Pages

BMS-345541

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is the current revision of this page, as edited by JJMC89 bot III (talk | contribs) at 19:52, 20 December 2023 (Moving Category:Merck brands to Category:Drugs developed by Merck per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands). The present address (URL) is a permanent link to this version.

Revision as of 19:52, 20 December 2023 by JJMC89 bot III (talk | contribs) (Moving Category:Merck brands to Category:Drugs developed by Merck per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compound
BMS-345541
Identifiers
IUPAC name
  • 4-(2′-Aminoethyl)amino-1,8-dimethylimidazoquinoxaline
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17N5
Molar mass255.325 g·mol
3D model (JSmol)
SMILES
  • n1c3c(n2c(cnc2c1NCCN)C)cc(cc3)C
InChI
  • InChI=1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18)
  • Key:PSPFQEBFYXJZEV-UHFFFAOYSA-N
  (what is this?)  (verify)

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.

References

  1. The Journal of Biological Chemistry. 2003. 278. 1450-1456.
  2. no studies found for: BMS-345541
Categories: